Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- <i>in vitro</i> and <i>in vivo</i> investigation using a taxane-resistant prostate cancer model.

Oncotarget · 2018 · PMC5790467 · PMID 29423050

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

2.322 ng/mg, p = 0.081) showed a trend increase after DTX-PIP combination.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.